- Home
- CYN vs SNSE Comparison
CYN vs SNSE Comparison
Compare CYN & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYN | SNSE |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 12.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYN | SNSE |
|---|---|---|
| Price | $1.50 | $29.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $72.50 |
| AVG Volume (30 Days) | 390.8K | ★ 580.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $368,138.00 | N/A |
| Revenue This Year | $31.96 | N/A |
| Revenue Next Year | $1,459.25 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $0.25 |
| 52 Week High | $41.54 | $36.76 |
Technical Indicators
Market Signals| Indicator | CYN | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 67.90 |
| Support Level | $1.33 | $7.94 |
| Resistance Level | $2.76 | $36.76 |
| Average True Range (ATR) | 0.11 | 4.36 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 45.12 | 75.01 |
Price Performance
Historical ComparisonAbout CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).